Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in 91É«ÇéƬ) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
The world's fastest spider tops 3.5 metres per second
2
Where, when and how to watch the 2026 solar eclipse
3
Babies are born with the neural foundations for maths
4
We’ve uncovered a master gene that switches on human development
5
Our verdict on The Selfish Gene: An unpopular piece of popular science
6
US government wants to have a useful quantum computer by 2028
7
Humans sleep the least of all apes – is it the secret to our success?
8
The race to understand how and when Thwaites glacier will collapse
9
The most detailed survey of the universe ever conducted starts now
10
I have a 100 per cent chance of getting cancer due to a rare gene
